

# Supplementary Materials

## **Parkinson's Families Project: a UK-wide study of early onset and familial Parkinson's disease**

Clodagh Towns, Zih-Hua Fang, Manuela M. X. Tan, Simona Jasaityte, Theresa M. Schmaderer, Eleanor J. Stafford, Miriam Pollard, Russel Tilney, Megan Hodgson, Lesley Wu, Robyn Labrum, Jason Hehir, James Polke, Lara M. Lange, Anthony H.V. Schapira, Kailash P. Bhatia, Parkinson's Families Project (PFP) Study Group, Global Parkinson's Genetics Program (GP2), Andrew B. Singleton, Cornelis Blauwendraat, Christine Klein, Henry Houlden, Nicholas W. Wood, Paul R. Jarman, Huw R. Morris\*, Raquel Real\*

\*Joint corresponding authors

## Table of Contents

Supplementary Methods .....	3
Supplementary References .....	5
Supplementary Figure 1 .....	6
Supplementary Figure 2 .....	7
Supplementary Figure 3 .....	8
Supplementary Figure 4 .....	9
Supplementary Table 1 .....	10
Supplementary Table 2 .....	12
Supplementary Table 3 .....	14
Supplementary Table 4 .....	15
Supplementary Table 5 .....	16
Supplementary Table 6 .....	18
Supplementary Table 7 .....	19
Supplementary Table 8 .....	20
Supplementary Table 9 .....	21
Supplementary Table 10 .....	23
Supplementary Table 11 .....	24
Supplementary Table 12 .....	26
PFP Study Group .....	27
GP2 Consortium .....	29

## Supplementary Methods

### Whole genome sequencing variant interpretation

In whole genome sequencing (WGS) data generated in the 100,000 Genomes Project, the “Parkinson Disease and Complex Parkinsonism” gene panel from Genomics England PanelApp (<https://panelapp.genomicsengland.co.uk/>) was used for gene prioritisation. Data processing, variant calling and variant interpretation were performed by Genomics England<sup>1</sup>. In data generated in the GP2 Monogenic Network, a curated panel of 74 genes (Supplementary Table 11) selected on the basis of association with PD or Parkinsonism was screened for potentially disease-causing variants. High-quality variants with a call rate >0.95, genotype quality (GQ) >20, read depth (DP) >5, and heterozygous allele balance (AB) between 0.2 and 0.8 were retained. Dominantly inherited protein coding SNVs/indels and splice site variants with the maximum credible genetic ancestry group allele frequency >0.005 were excluded<sup>2</sup>, as well as homozygous or potential compound heterozygous variants with >1 homozygote for the alternative allele in gnomAD v4.1.0 genomes (<https://gnomad.broadinstitute.org/>)<sup>3</sup>. In the first instance, we used Clinvar annotations to define pathogenicity. Cases were considered solved if variants classified as “Pathogenic” or “Likely Pathogenic” were present and the zygosity fit the known mode of inheritance for each gene. Novel variants and variants of unknown significance (VUS) were subjected to further variant interpretation according to the ACMG classification and the subsequent ACGS guidelines for variant classification in rare disease<sup>4,5</sup>. We used online tools such as Franklin (<https://franklin.genoox.com/>- Franklin by Genoox) and Varsome (<https://varsome.com/>) to assist in variant interpretation<sup>6</sup>. We also performed a literature search for additional information on the interrogated variants. When available, we incorporated segregation data into the decision tree. After this process, variants still classified as “unknown significance” were excluded. We use the term “compound heterozygosity” to define the presence of two pathogenic variants in recessive genes, even in cases where it was not possible to confirm that the variants were in *trans* due to lack of DNA from the parents. In cases where two pathogenic mutations were in very close proximity in the genome, we used the desktop application of Integrative Genomics Viewer (v2.17.4; <https://igv.org/>) to confirm if the variants were in the same allele (*cis*) or in separate alleles (*trans*)<sup>7</sup>. An example can be seen in Supplementary Figure 3.

### Validation of *ATXN2* and *ATXN3* short tandem repeats (STR)

For a subset of cases with STR calling from WGS, we additionally performed molecular analysis of short tandem repeats ( $n=33$  for *ATXN2* and  $n=34$  for *ATXN3*). Identification of repeat expansions in *ATXN2* and *ATXN3* genes was performed as previously described<sup>8</sup>. Briefly, amplification of the CAG trinucleotide repeat region was performed using fluorescent 6FAM-labelled primers (see Supplementary Table 12 for primer sequences). The amplified PCR fragments were sized by capillary electrophoresis on an ABI3730XL sequencer (Applied Biosystems) and the electropherogram peaks analyzed using GeneMapper<sup>®</sup> v5.0 software. Pathogenic expansions were defined using consensus thresholds from the literature<sup>9</sup>. Results from fragment size analysis


were used to validate the performance of the ExpansionHunter algorithm in whole genome sequencing data (Supplementary Figure 4).

### **Quantification of NeuroChip probe performance**


In a subset of 537 index cases, both NeuroChip genotyping array (NCA) and whole genome and/or targeted sequencing were available. We calculated the proportion of false positive and false negative genotype calls of all disease-causing mutations detected by NCA, considering whole genome or targeted sequencing as the reference (Supplementary Table 2). Of the 19 unique mutations detected using the NCA, there was a single probe that resulted in a false positive genotype (*GBA1* p.Ser235Pro). We then inspected the SNP graph for this variant in GenomeStudio™, which confirmed a poorly clustered SNP. Given its low sensitivity, we ignored results from this probe. Additionally, one of the probes (*GBA1* p.Arg159Trp) resulted in a false negative result. NCA-determined genotypes matched with sequencing data in 95.2% (40/42) of cases, indicating a very high sensitivity for most probes under assessment. However, given the limited number of probes included in the NCA array, its overall sensitivity to detect a pathogenic variant was 34.2%.

## Supplementary References

1. Caulfield, M. *et al.* National Genomic Research Library. figshare <https://doi.org/10.6084/M9.FIGSHARE.4530893.V7> (2020).
2. Whiffin, N. *et al.* Using high-resolution variant frequencies to empower clinical genome interpretation. *Genet. Med.* **19**, 1151–1158 (2017).
3. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).
4. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* **17**, 405–424 (2015).
5. Durkie, M. *et al.* ACGS best practice guidelines for variant classification in rare disease 2024. <https://www.acgs.uk.com/media/12533/uk-practice-guidelines-for-variant-classification-v12-2024.pdf>.
6. Kopanos, C. *et al.* VarSome: the human genomic variant search engine. *Bioinformatics* **35**, 1978–1980 (2019).
7. Robinson, J. T. *et al.* Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24–26 (2011).
8. Cagnoli, C. *et al.* Spinocerebellar ataxia tethering PCR: A rapid genetic test for the diagnosis of spinocerebellar ataxia types 1, 2, 3, 6, and 7 by PCR and capillary electrophoresis. *J. Mol. Diagn.* **20**, 289–297 (2018).
9. Sequeiros, J., Seneca, S. & Martindale, J. Consensus and controversies in best practices for molecular genetic testing of spinocerebellar ataxias. *Eur. J. Hum. Genet.* **18**, 1188–1195 (2010).




**Supplementary Figure 1. Final participant selection and investigations.** **a.** Flow chart of participant exclusions by participant type. **b.** Flow chart of investigations performed on index cases. **c.** Venn diagram of the overlap between each testing method in index cases. Targeted sequencing of a PD gene panel was available for an additional three index cases who did not have WGS. MLPA: multiplex ligation-dependent probe amplification assay; WGS: whole-genome sequencing; NCA: NeuroChip genotyping array.



**Supplementary Figure 2. Violin plots of Z-transformed PD polygenic risk scores (PD-PRS).** **a.** Monogenic ( $n=67$ ) vs mutation-negative ( $n=418$ ) PD. Logistic regression of z-PRS scores against mutation status, with age at onset, sex, and PC1-5 added as covariates **b.** Mutation-negative sEOPD ( $n=121$ ) vs fEOPD ( $n=60$ ) vs fLOPD ( $n=237$ ). Multinomial regression of z-PRS scores against disease category, with sex and PC1-5 added as covariates. Mutation negative cases exclude pathogenic or risk *GBA1* variant carriers, single heterozygous carriers of pathogenic variants in *PINK1* and *PRKN*, and cases that did not complete both WGS and MLPA. NCA data was used to compute the PD-PRS based on PD case-control GWAS summary statistics from Nalls *et al.* Statistical analysis was performed using logistic or multinomial regression, as appropriate. Box plots with median (centre line), upper and lower quartiles (box limits), 1.5x interquartile range (whiskers) and outliers (points) represented. \*,  $P<0.05$ .


Chr22

PLA2G6



**Supplementary Figure 3. Integrative Genomics Viewer window of a 105 bp region in *PLA2G2*.** Two missense pathogenic variants were detected at positions c.1061T>C and c.956C>T. Given the close proximity between the variants, the possibility that the two variants might be segregating together in an LD block was interrogated. In reads that span the entire 105 bp region, it is apparent that the variants are never present in the same read, confirming that they are not part of a haplotype and were inherited independently from each parent.





**Supplementary Figure 4. Correlation of short tandem repeat (STR) size determined by fragment analysis (FA) and Expansion Hunter (EH).** **a.** *ATXN2* STR length in 33 individuals (66 alleles) was  $21.5 \pm 2.2$  for FA and  $22.3 \pm 2.1$  for EH. Spearman correlation coefficient ( $\rho$ ) = 0.548, P-value =  $1.94 \times 10^{-6}$ . The red dotted lines indicate the threshold for pathogenicity ( $\geq 35$  repeats). **b.** *ATXN3* STR length in 34 individuals (68 alleles) was  $21.6 \pm 4.8$  for FA and  $17.6 \pm 4.8$  for EH ( $\rho = 0.999$ , P-value =  $< 2.2 \times 10^{-16}$ ). No alleles reached the threshold for pathogenicity ( $\geq 56$  repeats), which is therefore not represented in the plot.

**Supplementary Table 1.** Variant details of families carrying PD-causing pathogenic mutations

Family ID	Diagnosis	Group	Zygoty	Gene	Variant 1	Variant 2	Risk variants	Investigations
1	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
2 *	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
3	PD	sEOPD	HET	<i>LRRK2</i>	G2019S			NCA
4	PD	sEOPD	HET	<i>LRRK2</i>	G2019S			NCA
5	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
6	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
7	PD	sEOPD	HET	<i>LRRK2</i>	G2019S			NCA, WGS
8 ^	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
9 ^	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
10	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
11	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
12	PD	fEOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
13	PD	sEOPD	HET	<i>LRRK2</i>	G2019S			NCA
14	PD	sEOPD	HET	<i>LRRK2</i>	G2019S			NCA, WGS
15	PD	fLOPD	HET	<i>LRRK2</i>	G2019S		<i>GBA1</i> L29Afs*18	NCA, MLPA, WGS
16	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
17	PD	fEOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
18	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
19	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
20	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA, WGS
21	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
22	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA, WGS
23	Unaffected	NA	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
	Unaffected	NA	-	-	-			NCA, MLPA
24	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
25	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
26	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA
27	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			NCA, MLPA, WGS
28	PD	fLOPD	HET	<i>LRRK2</i>	G2019S			MLPA, WGS
29	PD	fLOPD	HET	<i>LRRK2</i>	R1441C			NCA, MLPA, WGS
30	PD	fLOPD	HET	<i>LRRK2</i>	N1437S			NCA, MLPA, WGS
31	PD	fLOPD	HET	<i>ATXN2</i>	(CAG)37			NCA, MLPA, WGS
	PD	fLOPD	-	-	-			NCA, MLPA
32	PD	fLOPD	HET	<i>ATXN2</i>	(CAG)39			NCA, MLPA, WGS
33	PD	fLOPD	HET	<i>ATXN2</i>	(CAG)37			NCA, MLPA, WGS
34	PD	fLOPD	HET	<i>RAB32</i>	Ser71Arg			NCA, MLPA, WGS
35	PD	sEOPD	HOM	<i>PNPLA6</i>	P1297S	P1297S		NCA, MLPA, WGS
36	PD	fEOPD	COMP_HET	<i>SPG7</i>	N288*	A510V		NCA, MLPA, WGS
37	Dystonia-Parkinsonism	sEOPD	COMP_HET	<i>PLA2G6</i>	T319M	L354P		NCA, MLPA, WGS
38	PD	fEOPD	COMP_HET	<i>PRKN</i>	C166Y	Exon 1-3 deletion		NCA, MLPA, WGS
	PD	fEOPD	COMP_HET	<i>PRKN</i>	Exon 3-4 deletion	C253Y		NCA, MLPA, WGS
39	PD	fEOPD	COMP_HET	<i>PRKN</i>	Exon 3-4 deletion	C253Y		NCA, MLPA, NGS gene panel
	PD	fEOPD	COMP_HET	<i>PRKN</i>	Exon 3-4 deletion	C253Y		NCA, MLPA, WGS

**Supplementary Table 1.** Variant details of families carrying PD-causing pathogenic mutations

Family ID	Diagnosis	Group	Zygoty	Gene	Variant 1	Variant 2	Risk variants	Investigations
	Unaffected	NA	-	-	-	-		NCA, MLPA
	Unaffected	NA	HET	-	Exon 3-4 deletion	-		NCA, MLPA
40	PD	sEOPD	HOM	<i>PRKN</i>	Q34Rfs*	Q34Rfs*		NCA, MLPA, WGS
41	PD	sEOPD	COMP_HET	<i>PRKN</i>	G284R	C166Hfs*18	<i>GBA1</i> T408M	NCA, WGS
42	PD	sEOPD	COMP_HET	<i>PRKN</i>	G430D	P113fs*51		NCA, MLPA, WGS
43	PD	sEOPD	COMP_HET	<i>PRKN</i>	N52Mfs*59	W74Cfs*8		NCA, MLPA, NGS gene panel
44 *	PD	sEOPD	COMP_HET	<i>PRKN</i>	P113fs*51	Exon 2 deletion		NCA, MLPA, WGS
45	PD	sEOPD	HOM	<i>PRKN</i>	R275W	R275W		NCA, MLPA
	Unaffected	NA	HET	<i>PRKN</i>	R275W	-		NCA, MLPA
46	PD	fEOPD	COMP_HET	<i>PRKN</i>	G430D	R275W		NCA, MLPA
	Unaffected	NA	HET	<i>PRKN</i>	G430D	-		NCA, MLPA
47	PD	sEOPD	COMP_HET	<i>PRKN</i>	R275W	P113fs*51		NCA, MLPA, WGS
	Unaffected	NA	HET	<i>PRKN</i>	R275W	-		NCA, MLPA
	Unaffected	NA	HET	<i>PRKN</i>	Exon 3 deletion †	-		NCA, MLPA
48	PD	fEOPD	COMP_HET	<i>PRKN</i>	R275W	Exon 4 deletion		NCA, MLPA, WGS
49	PD	sEOPD	COMP_HET	<i>PRKN</i>	R275W	Exon 4 deletion		NCA, MLPA, WGS
50	PD	fEOPD	COMP_HET	<i>PRKN</i>	R275W	Exon 5 deletion		NCA, MLPA, WGS
51	PD	fEOPD	COMP_HET	<i>PRKN</i>	R275W	Exon 8 deletion		NCA, MLPA, WGS
52	PD	sEOPD	HOM	<i>PRKN</i>	R275W	R275W		NCA, MLPA
53	PD	fEOPD	COMP_HET	<i>PRKN</i>	R42P	Exon 3 duplication		NCA, MLPA, WGS
54	PD	sEOPD	COMP_HET	<i>PRKN</i>	T240M & P437L	Exon 2 deletion		NCA, MLPA, WGS
55	PD	sEOPD	COMP_HET	<i>PRKN</i>	Exon 2 deletion	Exon 4 deletion		NCA, MLPA, WGS
56	PD	fEOPD	COMP_HET	<i>PRKN</i>	G430D	N52Mfs*29		NCA, MLPA, WGS
	Unaffected	NA	HET	<i>PRKN</i>	G430D	-		NCA, MLPA
57	PD	fEOPD	COMP_HET	<i>PRKN</i>	P113fs*51	Exon 5 deletion		NCA, MLPA, WGS
58	PD	sEOPD	COMP_HET	<i>PRKN</i>	Exons 3-4 deletion	Exon 8 deletion	<i>GBA1</i> T408M	NCA, MLPA, WGS
59	PD	fEOPD	COMP_HET	<i>PRKN</i>	Exon 3 deletion	Exons 5-7 deletion		NCA, MLPA
60	PD	sEOPD	COMP_HET	<i>PRKN</i>	R275W	P113fs*51		NCA, MLPA, WGS
61	PD	fEOPD	COMP_HET	<i>PRKN</i>	R275W	c.1083+1G>T		NCA, MLPA, WGS
	PD	fEOPD	COMP_HET	<i>PRKN</i>	R275W	c.1083+1G>T		NCA, MLPA, WGS
62	PD	sEOPD	COMP_HET	<i>PRKN</i>	Exon 2 deletion	Exons 4-7 deletion		NCA, MLPA, WGS
63	PD	sEOPD	COMP_HET	<i>PRKN</i>	Exon 3 duplication	Exon 7 duplication		MLPA, WGS
64	PD	sEOPD	HOM	<i>PINK1</i>	Y258*	Y258*		NCA, MLPA
65 *	PD	fEOPD	HOM	<i>PINK1</i>	W90Lfs*12	W90Lfs*12		NCA, MLPA, WGS
66	PD	sEOPD	HET	<i>SNCA</i>	Duplication			NCA, MLPA, WGS
67	PD	sEOPD	HET	<i>SNCA</i>	Duplication			NCA, MLPA
68	PD	fLOPD	HET	<i>VCP</i>	R159C			NCA, MLPA, WGS
69	PD	fEOPD	HET	<i>GCH1</i>	L224R		<i>GBA1</i> R296Q	NCA, MLPA, WGS

AAO = Age at onset, AAC = age at consent, NCA = NeuroChip array, MLPA = Multiplex ligation-dependent probe amplification, WGS = whole-genome sequencing, NGS = next-generation sequencing, AJ = Ashkenazi Jewish, EUR = European, SAS = South Asian, HET = heterozygous, HOM = homozygous, COMP\_HET = compound heterozygous, NA = Not applicable. \*Consanguineous family. ^Families found to be related by kinship analysis. †The frameshift deletion c.337\_376del (P113fs\*51) is located in exon 3 of the *PRKN* gene and disrupts the binding of MLPA exon 3 probe, causing a false positive exon 3 deletion in MLPA.

**Supplementary Table 2.** PD-associated variants with probes in NeuroChip genotyping array**A. Variants detected at least once**

Gene	Chr	Nucleotide change	Amino acid change	Clinvar classification	MDSGene classification	FP/total calls	FN/total calls
PRKN	6	c.1289G>A	p.Gly430Asp	Pathogenic		0/2	0/2
PRKN	6	c.850G>C	p.Gly284Arg	Pathogenic		0/1	0/1
PRKN	6	c.823C>T	p.Arg275Trp	Pathogenic	Definitely pathogenic	0/8	0/8
PRKN	6	c.633A>T	p.Lys211Asn	Pathogenic	Definitely pathogenic	0/1	0/1
PRKN	6	c.125G>C	p.Arg42Pro	Pathogenic	Definitely pathogenic	0/1	0/1
PRKN	6	c.1310C>T	p.Pro437Leu	Conflicting interpretations	Definitely pathogenic	0/7	0/7
PRKN	6	c.101_102del	p.Gln34fs*	Pathogenic		0/1	0/1
PRKN	6	c.220_221dup	p.Trp74fs*	Pathogenic/Likely pathogenic		0/1	0/1
LRRK2	12	c.4321C>T	p.Arg1441Cys	Pathogenic	Definitely pathogenic	0/1	0/1
LRRK2	12	c.6055G>A	p.Gly2019Ser	Pathogenic	Definitely pathogenic	0/4	0/4
VCP	9	c.475C>T	p.Arg159Cys	Pathogenic		0/1	0/1
GBA1	1	c.1504C>T	p.Arg502Cys	Pathogenic		0/4	0/4
GBA1	1	c.1342G>C	p.Asp448His	Pathogenic/Likely pathogenic		0/1	0/1
GBA1	1	c.1246G>A	p.Gly416Ser	Pathogenic		0/1	0/1
GBA1	1	c.1226A>G	p.Asn409Ser	Pathogenic/Likely pathogenic		0/3	0/3
GBA1	1	c.1085C>T	p.Thr362Ile	Pathogenic		0/1	0/1
GBA1	1	c.887G>A	p.Arg296Gln	Pathogenic		0/1	0/1
GBA1	1	c.703T>C	p.Ser235Pro	Pathogenic		1/1	0/1
GBA1	1	c.84dup	p.Leu29fs*	Pathogenic		0/1	0/1
GBA1	1	c.475C>T	p.Arg159Trp	Pathogenic		0/1	1/1

**B. Variants not detected**

Gene	Chr	c.DNA change	Amino acid change	Clinvar classification	MDSGene classification
PRKN	6	c.1359G>A	p.Trp453*	Likely pathogenic	Definitely pathogenic
PRKN	6	c.1292G>T	p.Cys431Phe	Pathogenic	
PRKN	6	c.931C>T	p.Gln311*	Pathogenic	Definitely pathogenic
PRKN	6	c.635G>A	p.Cys212Tyr	Pathogenic	Definitely pathogenic
PRKN	6	c.483A>T	p.Lys161Asn	Pathogenic	
PRKN	6	c.98G>A	p.Arg33Gln	Pathogenic	
PRKN	6	c.1334G>A	p.Trp445*	Pathogenic	
PRKN	6	c.1321T>C	p.Cys441Arg	Pathogenic	
PRKN	6	c.1252T>C	p.Cys418Arg	Likely pathogenic	
PRKN	6	c.1244C>A	p.Thr415Asn	Likely pathogenic	
PRKN	6	c.865T>G	p.Cys289Gly		Definitely pathogenic
PINK1	1	c.502G>C	p.Ala168Pro	Pathogenic	Definitely pathogenic
PINK1	1	c.650C>A	p.Ala217Asp	Pathogenic	
PINK1	1	c.736C>T	p.Arg246*	Pathogenic	
PINK1	1	c.774C>A	p.Tyr258*	Pathogenic	
PINK1	1	c.813C>A	p.His271Gln	Pathogenic	Definitely pathogenic
PINK1	1	c.926G>A	p.Gly309Asp	Pathogenic	Definitely pathogenic
PINK1	1	c.938C>T	p.Thr313Met	Pathogenic	
PINK1	1	c.1040T>C	p.Leu347Pro	Pathogenic	Definitely pathogenic
PINK1	1	c.1311G>A	p.Trp437*	Pathogenic	Definitely pathogenic
PINK1	1	c.1366C>T	p.Gln456*	Pathogenic	Definitely pathogenic
PINK1	1	c.1474C>T	p.Arg492*	Pathogenic	
PINK1	1	c.1162T>C	p.Cys388Arg	Likely pathogenic	Definitely pathogenic
PINK1	1	c.377A>C	p.Gln126Pro	Likely pathogenic	
PINK1	1	c.509T>G	p.Val170Gly		Definitely pathogenic
PINK1	1	c.718G>A	p.Glu240Lys		Definitely pathogenic
PINK1	1	c.1226G>T	p.Gly409Val		Definitely pathogenic
PINK1	1	c.1250A>G	p.Glu417Gly		Definitely pathogenic
PARK7	1	c.29T>C	p.Leu10Pro		Definitely pathogenic
PARK7	1	c.78G>A	p.Met26Ile	Pathogenic	Definitely pathogenic
PARK7	1	c.115G>T	p.Ala39Ser	Pathogenic	
PARK7	1	c.192G>C	p.Glu64Asp	Pathogenic	Definitely pathogenic
PARK7	1	c.497T>C	p.Leu166Pro	Pathogenic	Definitely pathogenic
PARK7	1	c.133C>T	p.Gln45*	Pathogenic	
ATP13A2	1	c.2629G>A	p.Gly877Arg	Pathogenic	
ATP13A2	1	c.2561T>G	p.Met854Arg	Pathogenic	
ATP13A2	1	c.1903C>T	p.Gln635*	Pathogenic	
ATP13A2	1	c.3176T>G	p.Leu1059Arg	Likely pathogenic	Definitely pathogenic
ATP13A2	1	c.2529+1G>A		Likely pathogenic	
ATP13A2	1	c.477+2T>G		Pathogenic/Likely pathogenic	
ATP13A2	1	c.2113C>T	p.Gln705Ter	Pathogenic	
FBXO7	22	c.65C>T	p.Thr22Met	Pathogenic	Definitely pathogenic
FBXO7	22	c.1492C>T	p.Arg498*	Pathogenic	Definitely pathogenic
FBXO7	22	c.961C>T	p.Arg321*	Likely pathogenic	
FBXO7	22	c.1033C>T	p.Arg345*	Likely pathogenic	
SNCA	4	c.157G>A	p.Ala53Thr	Pathogenic	Definitely pathogenic
SNCA	4	c.152G>A	p.Gly51Asp	Pathogenic	Definitely pathogenic

<i>SNCA</i>	4	c.136G>A	p.Glu46Lys	Pathogenic	
<i>SNCA</i>	4	c.88G>C	p.Ala30Pro	Pathogenic	
<i>LRRK2</i>	12	c.3364A>G	p.Ile1122Val	Pathogenic	
<i>LRRK2</i>	12	c.5096A>G	p.Tyr1699Cys	Pathogenic	Definitely pathogenic
<i>LRRK2</i>	12	c.6059T>C	p.Ile2020Thr	Pathogenic	Definitely pathogenic
<i>VPS35</i>	16	c.1858G>A	p.Asp620Asn	Pathogenic	Definitely pathogenic
<i>DCTN1</i>	2	c.221A>C	p.Gln74Pro	Pathogenic	
<i>DCTN1</i>	2	c.212G>A	p.Gly71Glu	Pathogenic	
<i>DCTN1</i>	2	c.211G>A	p.Gly71Arg	Pathogenic	Definitely pathogenic
<i>DCTN1</i>	2	c.200G>A	p.Gly67Asp	Pathogenic	
<i>DCTN1</i>	2	c.175G>A	p.Gly59Ser	Pathogenic	
<i>DCTN1</i>	2	c.156T>G	p.Phe52Leu	Pathogenic	
<i>DCTN1</i>	2	c.3823C>T	p.Arg1275Cys	Likely pathogenic	
<i>DCTN1</i>	2	c.175G>C	p.Gly59Arg	Pathogenic	
<i>VCP</i>	9	c.695C>A	p.Ala232Glu	Pathogenic	
<i>VCP</i>	9	c.572G>A	p.Arg191Gln	Pathogenic/Likely pathogenic	
<i>VCP</i>	9	c.476G>A	p.Arg159His	Pathogenic	
<i>VCP</i>	9	c.463C>T	p.Arg155Cys	Pathogenic	
<i>VCP</i>	9	c.283C>G	p.Arg95Gly	Pathogenic	
<i>VCP</i>	9	c.277C>T	p.Arg93Cys	Pathogenic	
<i>VCP</i>	9	c.472A>G	p.Met158Val	Pathogenic	
<i>VCP</i>	9	c.469G>C	p.Gly157Arg	Pathogenic	
<i>VCP</i>	9	c.284G>A	p.Arg95His	Likely pathogenic	
<i>VCP</i>	9	c.278G>A	p.Arg93His	Likely pathogenic	
<i>VCP</i>	9	c.553G>A	p.Glu185Lys	Likely pathogenic	
<i>VCP</i>	9	c.466G>A	p.Gly156Ser	Pathogenic	
<i>GBA1</i>	1	c.1549G>A	p.Gly517Ser	Pathogenic	
<i>GBA1</i>	1	c.1505G>A	p.Arg502His	Pathogenic/Likely pathogenic	
<i>GBA1</i>	1	c.1503C>G	p.Asn501Lys	Likely pathogenic	
<i>GBA1</i>	1	c.1448T>G	p.Leu483Arg	Pathogenic/Likely pathogenic	
<i>GBA1</i>	1	c.1297G>T	p.Val433Leu	Pathogenic/Likely pathogenic	
<i>GBA1</i>	1	c.1271T>C	p.Leu424Pro	Likely pathogenic	
<i>GBA1</i>	1	c.1228C>G	p.Leu410Val	Pathogenic	
<i>GBA1</i>	1	c.1208G>C	p.Ser403Thr	Likely pathogenic	
<i>GBA1</i>	1	c.1192C>T	p.Arg398*	Pathogenic	
<i>GBA1</i>	1	c.1174C>T	p.Arg392Trp	Pathogenic	
<i>GBA1</i>	1	c.1174C>G	p.Arg392Gly	Pathogenic	
<i>GBA1</i>	1	c.1171G>C	p.Val391Leu	Pathogenic/Likely pathogenic	
<i>GBA1</i>	1	c.1090G>A	p.Gly364Arg	Likely pathogenic	
<i>GBA1</i>	1	c.983C>T	p.Pro328Leu	Pathogenic	
<i>GBA1</i>	1	c.928A>G	p.Ser310Gly	Likely pathogenic	
<i>GBA1</i>	1	c.896T>C	p.Ile299Thr	Likely pathogenic	
<i>GBA1</i>	1	c.870C>A	p.Phe290Leu	Pathogenic	
<i>GBA1</i>	1	c.764T>A	p.Phe255Tyr	Pathogenic/Likely pathogenic	
<i>GBA1</i>	1	c.709A>G	p.Lys237Glu	Pathogenic	
<i>GBA1</i>	1	c.701G>A	p.Gly234Glu	Likely pathogenic	
<i>GBA1</i>	1	c.681T>G	p.Asn227Lys	Pathogenic	
<i>GBA1</i>	1	c.680A>G	p.Asn227Ser	Pathogenic/Likely pathogenic	
<i>GBA1</i>	1	c.625C>T	p.Arg209Cys	Pathogenic	
<i>GBA1</i>	1	c.509G>T	p.Arg170Leu	Likely pathogenic	
<i>GBA1</i>	1	c.497A>T	p.Asp166Val	Likely pathogenic	
<i>GBA1</i>	1	c.415G>C	p.Ala139Pro	Likely pathogenic	
<i>GBA1</i>	1	c.254G>A	p.Gly85Glu	Pathogenic	
<i>GBA1</i>	1	c.160G>T	p.Val54Leu	Pathogenic	
<i>GBA1</i>	1	c.914C>T	p.Pro305Leu	Likely pathogenic	
<i>GBA1</i>	1	c.894C>A	p.Phe298Leu	Likely pathogenic	
<i>GBA1</i>	1	c.1249T>G	p.Trp417Gly	Pathogenic/Likely pathogenic	
<i>GBA1</i>	1	c.661C>A	p.Pro221Thr	Pathogenic/Likely pathogenic	
<i>GBA1</i>	1	c.314T>C	p.Leu105Pro	Likely pathogenic	
<i>GBA1</i>	1	c.1300C>T	p.Arg434Cys	Likely pathogenic	
<i>GBA1</i>	1	c.1162G>A	p.Glu388Lys	Likely pathogenic	
<i>GBA1</i>	1	c.721G>A	p.Gly241Arg	Pathogenic/Likely pathogenic	

Pathogenic variants in genes associated with monogenic PD, classified by ClinVar as pathogenic/likely pathogenic and/or MDSGene as definitively pathogenic. *GBA1* variants classified by ClinVar as pathogenic for Gaucher's disease or risk factors for PD. The proportion of false positive (FP) and false negative (FN) genotype calls were calculated for the 20 probes targeting mutations detected in the 537 individuals who underwent both NeuroChip array genotyping and sequencing. There were 40/42 (95.2%) matched genotypes and 90% (18/20) of probes had a sensitivity and specificity of 100%.

**Supplementary Table 3.** Clinical features of index cases with pathogenic variants in PD-related genes

	<i>SNCA</i>	<i>GCH1</i>	<i>ATXN2</i>	<i>VCP</i>	<i>PLA2G6</i>	<i>PNPLA6</i>	<i>SPG7</i>	<i>PINK1</i>
Index cases (N)	2	1	3	1	1	1	1	2
Age at Onset (mean ± sd) *	40.0 (5.7)	31-35	56.3 (3.79)	56-60	31-35	26-30	21-25	36.5 (12.0)
Motor Features (mean ± sd)								
MDS-UPDRS Part III	49	31	45 (NA)	38	NA	23	NA	16
Motor Severity Score	4.1	3.4	3.7 (NA)	4.7	NA	2.9	NA	0.6
Motor Subtype (%)								
Tremor-dominant	0	100	0	0	0	0	NA	NA
PIGD-dominant	100	0	100	100	0	100	NA	NA
Intermediate	0	0	0	0	0	0	NA	NA
Hoehn and Yahr stage (%)								
0-1.5	0	0	100	0	NA	0	NA	0
2 or 2.5	0	100	0	100	NA	100	NA	100
3+	100	0	0	0	NA	0	NA	0
Motor Complications (%)								
Dyskinesias	100	0	0	0	NA	100	NA	100
Motor fluctuations	100	100	100	100	NA	0	NA	0
Off dystonia	100	100	0	0	NA	0	NA	0
Motor Aspects of Daily Living (mean ± sd)	28	20	15.3 (11.1)	17	16	20	NA	NA
Autonomic Dysfunction (%)								
Orthostatic Hypotension	100	100	66.7	100	100	100	100	100
Constipation	100	100	100	0	100	0	100	100
Urinary Dysfunction	100	100	100	0	100	0	100	100
REM Sleep Behaviour Disorder (%)	100	100	66.7	0	100	100	0	100
Neuropsychiatric Symptoms (%)								
Apathy	100	100	50	0	NA	0	0	0
Depression	100	100	0	0	NA	0	0	0
Anxiety	100	100	0	0	NA	0	0	0
Dopamine Dysregulation Syndrome	100	100	0	0	NA	0	0	0
Hallucinations	100	100	0	100	NA	0	0	0
MoCA score (mean ± sd)	27	26	18.5 (0.7)	30	28	26	25	23

MDS-UPDRS items were used to define the following clinical features: dyskinesias (items 4.1+4.2 >0); motor fluctuations (items 4.3+4.4+4.5 >0); off-dystonia (item 4.6 >0); orthostatic hypotension (item 1.12 >0); constipation (item 1.11 >0); urinary dysfunction (item 1.10 >0); apathy (item 1.5 >0); depression (item 1.3 >1); anxiety (item 1.4 >1), impulse control disorder (item 1.6 >0); hallucinations (item 1.2 >0 and <4). Motor severity scores are MDS-UPDRS part III scores divided by disease duration in years. Motor subtypes were defined according to Stebbins et al., 2013. Motor aspects of daily living scores are the sum of MDS-UPDRS part II items. REM sleep behaviour disorder was defined as RBDSQ score >5. \* When N = 1, Age at Onset is presented as a 5-year age bracket.

**Supplementary Table 4.** Variant details of families carrying a single heterozygous pathogenic variant in *PINK1* and *PRKN*

Family ID	Diagnosis	Group	Gene	Variant 1	Variant 2	Risk variants	Investigations
1	PD	fEOPD	<i>PINK1</i>	Exon 5 deletion		<i>GBA</i> N409S	NCA, MLPA, WGS
	Unaffected	NA	-	-		<i>GBA</i> N409S	NCA, MLPA
	Unaffected	NA	<i>PINK1</i>	Exon 5 deletion		-	NCA, MLPA
2	PD	fLOPD	<i>PINK1</i>	c.1124-1G>A			NCA, MLPA, WGS
3	PD	fLOPD	<i>PRKN</i>	K211N		<i>GBA1</i> E365K	NCA, MLPA, WGS
4	PD	fEOPD	<i>PRKN</i>	P437L			NCA, MLPA, WGS
5	PD	fEOPD	<i>PRKN</i>	P437L	-		NCA, MLPA, WGS
	PD	fLOPD	<i>PRKN</i>	P437L	P132Tfs*9		NCA, MLPA, WGS
6	PD	fLOPD	<i>PRKN</i>	P437L			NCA, MLPA, WGS
7	PD	fLOPD	<i>PRKN</i>	P437L			NCA, MLPA, WGS
8	PD	fLOPD	<i>PRKN</i>	P437L			NCA, MLPA, WGS
9	PD	fLOPD	<i>PRKN</i>	R275W		<i>GBA1</i> T408M	NCA, MLPA, WGS
10	PD	fLOPD	<i>PRKN</i>	Exons 1-2 duplication			NCA, MLPA, WGS
11	PD	sEOPD	<i>PRKN</i>	Exon 1 deletion		<i>GBA1</i> L483P	NCA, MLPA, WGS
12	PD	fLOPD	<i>PRKN</i>	Exon 2 deletion			NCA, MLPA, WGS
13	PD	sEOPD	<i>PRKN</i>	Exon 3 deletion			NCA, MLPA, WGS
14	PD	fLOPD	<i>PRKN</i>	Exons 3-6 duplication			NCA, MLPA, WGS

AAO = Age at onset, AAC = age at consent, NCA = NeuroChip array, MLPA = Multiplex ligation-dependent probe amplification, WGS = whole-genome sequencing, EUR = European CAS = Central Asian, NA = Not applicable.

Only index cases with completed MLPA and WGS were included.

**Supplementary Table 5. Unique variants identified in index cases**

MOI	Gene	Variant	Allele frequency (N alleles)			Total
			sEOPD	fEOPD	fLOPD	
<i>Autosomal dominant</i>						
	<i>LRRK2</i>	G2019S	1.2 (5)	0.9 (2)	2.6 (21)	1.9 (28)
	<i>LRRK2</i>	R1441C	0	0	0.1 (1)	0.1 (1)
	<i>LRRK2</i>	N1437S	0	0	0.1 (1)	0.1 (1)
	<i>ATXN2</i>	CAG repeat	0	0	0.4 (3)	0.2 (3)
	<i>SNCA</i>	Duplication	0.5 (2)	0	0	0.1 (2)
	<i>VCP</i>	R159C	0	0	0.1 (1)	0.1 (1)
	<i>GCH1</i>	L224R	0	0.4 (1)	0	0.1 (1)
	<i>RAB32</i>	S71R	0	0	0.1 (1)	0.1 (1)
<i>Autosomal recessive</i>						
	<i>PARK2</i>	R275W	2 (8)	2.2 (5)	0.1 (1)	1 (14)
	<i>PARK2</i>	P437L	0.2 (1)	1.3 (3)	0.8 (6)	0.7 (10)
	<i>PARK2</i>	P113fs	1 (4)	0.4 (1)	0	0.3 (5)
	<i>PARK2</i>	G430D	0.2 (1)	0.9 (2)	0	0.2 (3)
	<i>PARK2</i>	<b>C166Hfs*18</b>	0.2 (1)	0	0	0.1 (1)
	<i>PARK2</i>	C166Y	0	0.4 (1)	0	0.1 (1)
	<i>PARK2</i>	C253Y	0	0.4 (1)	0	0.1 (1)
	<i>PARK2</i>	G284R	0.2 (1)	0	0	0.1 (1)
	<i>PARK2</i>	K211N	0	0	0.1 (1)	0.1 (1)
	<i>PARK2</i>	N52fs	0.2 (1)	0.4 (1)	0	0.1 (2)
	<i>PARK2</i>	Q34Rfs	0.5 (2)	0	0	0.1 (2)
	<i>PARK2</i>	R42P	0	0.4 (1)	0	0.1 (1)
	<i>PARK2</i>	T240M	0.2 (1)	0	0	0.1 (1)
	<i>PARK2</i>	W74Cfs*8	0.2 (1)	0	0	0.1 (1)
	<i>PARK2</i>	<b>c.1083+1G&gt;T</b>	0	0.4 (1)	0	0.1 (1)
	<i>PARK2</i>	Exon 2 deletion	1.2 (5)	0	0.1 (1)	0.4 (6)
	<i>PARK2</i>	Exon 3 deletion	0.2 (1)	0.9 (2)	0	0.2 (3)
	<i>PARK2</i>	Exon 4 deletion	0.5 (2)	0.4 (1)	0	0.2 (3)
	<i>PARK2</i>	Exon 8 deletion	0.5 (2)	0.4 (1)	0	0.2 (3)
	<i>PARK2</i>	Exon 2 duplication	0	0	0.2 (2)	0.1 (2)
	<i>PARK2</i>	Exon 3 duplication	0.2 (1)	0.4 (1)	0	0.1 (2)
	<i>PARK2</i>	Exons 3-4 deletion	0.2 (1)	0.4 (1)	0	0.1 (2)
	<i>PARK2</i>	Exons 3-6 duplication	0	0.4 (1)	0.1 (1)	0.1 (2)
	<i>PARK2</i>	Exon 5 deletion	0	0.9 (2)	0	0.1 (2)
	<i>PARK2</i>	Exon 1 deletion	0.2 (1)	0	0	0.1 (1)
	<i>PARK2</i>	Exons 1-2 duplication	0	0	0.1 (1)	0.1 (1)
	<i>PARK2</i>	Exons 1-3 deletion	0	0.4 (1)	0	0.1 (1)
	<i>PARK2</i>	Exons 4-7 deletion	0.2 (1)	0	0	0.1 (1)
	<i>PARK2</i>	Exons 5-7 deletion	0	0.4 (1)	0	0.1 (1)
	<i>PARK2</i>	Exons 7 duplication	0.2 (1)	0	0	0.1 (1)
	<i>PINK1</i>	W90Lfs*12	0	0.9 (2)	0	0.1 (2)
	<i>PINK1</i>	Y258*	0.5 (2)	0	0	0.1 (2)
	<i>PINK1</i>	<b>c.1124-1G&gt;A</b>	0	0	0.1 (1)	0.1 (1)
	<i>PINK1</i>	Exon 5 deletion	0	0.9 (2)	0	0.1 (2)
	<i>PNPLA6</i>	P1297S	0.5 (2)	0	0	0.1 (2)
	<i>PLA2G6</i>	L354P	0.2 (1)	0	0	0.1 (1)
	<i>PLA2G6</i>	T319M	0.2 (1)	0	0	0.1 (1)
	<i>SPG7</i>	A510V	0	0.4 (1)	0	0.1 (1)
	<i>SPG7</i>	N288*	0	0.4 (1)	0	0.1 (1)
<i>PD risk</i>						
	<i>GBA1</i>	E365K	1.5 (6)	1.8 (4)	1.6 (13)	1.6 (23)
	<i>GBA1</i>	T408M	1.5 (6)	1.8 (4)	1 (8)	1.3 (18)
	<i>GBA1</i>	L483P	1.5 (6)	0	0.8 (6)	0.8 (12)
	<i>GBA1</i>	N409S	0.2 (1)	0.9 (2)	0.2 (2)	0.3 (5)
	<i>GBA1</i>	A163fs	0	0	0.1 (1)	0.1 (1)
	<i>GBA1</i>	D448H	0	0	0.1 (1)	0.1 (1)
	<i>GBA1</i>	<b>G152A</b>	0.2 (1)	0	0	0.1 (1)
	<i>GBA1</i>	G152E	0.2 (1)	0	0	0.1 (1)
	<i>GBA1</i>	G416S	0	0.4 (1)	0	0.1 (1)
	<i>GBA1</i>	IVS2DS+1G-A	0	0.4 (1)	0	0.1 (1)
	<i>GBA1</i>	L29Afs*18	0	0	0.1 (1)	0.1 (1)
	<i>GBA1</i>	M162T	0	0	0.1 (1)	0.1 (1)
	<i>GBA1</i>	P138Lfs*62	0.5 (2)	0	0	0.1 (2)
	<i>GBA1</i>	<b>P430H</b>	0	0	0.1 (1)	0.1 (1)
	<i>GBA1</i>	<b>P454A</b>	0.2 (1)	0	0	0.1 (1)
	<i>GBA1</i>	R159Q	0	0	0.1 (1)	0.1 (1)
	<i>GBA1</i>	R159W	0	0.4 (1)	0	0.1 (1)
	<i>GBA1</i>	R296Q	0	0.4 (1)	0	0.1 (1)
	<i>GBA1</i>	R398*	0	0	0.1 (1)	0.1 (1)
	<i>GBA1</i>	R502C	0.2 (1)	0	0.4 (3)	0.3 (4)



**Supplementary Table 5.** Unique variants identified in index cases

MOI	Gene	Variant	Allele frequency (N alleles)			Total
			sEOPD	fEOPD	fLOPD	
<i>PD risk</i>	<i>GBA1</i>	T362I	0	0.4 (1)	0	0.1 (1)
	<i>GBA1</i>	<b>Y244Tfs*10</b>	0	0	0.1 (1)	0.1 (1)
	<i>GBA1</i>	<b>Y352*</b>	0	0	0.1 (1)	0.1 (1)
	<i>GBA1</i>	c.1263del	0	0.4 (1)	0	0.1 (1)
	<i>GBA1</i>	<b>V333Rfs*4</b>	0	0.4 (1)	0	0.1 (1)

sEOPD = sporadic early-onset PD, fEOPD = familial early-onset PD, fLOPD = familial late-onset PD, MOI = mode of inheritance.

Bold indicates novel variants. An additional novel *PRKN* variant (P132Tfs\*9) was exclusively identified in an affected relative and is not listed here.

**Supplementary Table 6.** Frequency of pathogenic and risk factor variants identified in index cases

	sEOPD N = 205	fEOPD N = 113	fLOPD N = 400	Total N = 718
<b>PD-causing genes (%)</b>	<b>12.2</b>	<b>14.2</b>	<b>7</b>	<b>9.6</b>
<i>LRRK2</i>	2.4	1.8	5.8	4.2
<i>SNCA</i>	1	0	0	0.3
<i>VCP</i>	0	0	0.2	0.1
<i>ATXN2</i>	0	0	0.8	0.4
<i>GCH1</i>	0	0.9	0	0.1
<i>RAB32</i>	0	0	0.2	0.1
<i>PRKN</i> (biallelic)	7.3	9.7	0	3.6
<i>PINK1</i> (biallelic)	0.5	0.9	0	0.3
<i>PNPLA6</i> (biallelic)	0.5	0	0	0.1
<i>PLA2G6</i> (biallelic)	0.5	0	0	0.1
<i>SPG7</i> (biallelic)	0	0.9	0	0.1
<b>Single recessive variants (%) ‡</b>	<b>1.3</b>	<b>3.3</b>	<b>3</b>	<b>1.9</b>
<i>PRKN</i> (monoallelic)	1.3	2.2	2.7	1.7
<i>PINK1</i> (monoallelic)	0	1.1	0.3	0.3
<b><i>GBA1</i> risk variants (%) †</b>	<b>10.2</b>	<b>13.3</b>	<b>9.2</b>	<b>10.2</b>
PD risk variants	4.9	7.1	4.5	5
Mild GD-causing mutations	0.5	1.8	0.5	0.7
Severe GD-causing mutations	2.9	3.5	3.2	3.2
Unknown severity	2	0.9	1	1.3

‡Excludes single recessive pathogenic variants in cases not fully investigated with MLPA and WGS (n=9). †Excludes *GBA1* mutations that coexist with pathogenic mutations in *LRRK2* (n=1), *PRKN* biallelic (n=2), *PRKN* monoallelic (n=3), *PINK1* monoallelic (n=1) and *GCH1* (n=1). sEOPD = sporadic early-onset PD, fEOPD = familial early-onset PD, fLOPD = familial late-onset PD, GD = Gaucher disease.

**Supplementary Table 7.** Demographic characteristics of index cases by gene

	<i>SNCA</i>	<i>VCP</i>	<i>ATXN2</i>	<i>RAB32</i>	<i>LRRK2</i>	<i>PNPLA6</i>	<i>PINK1</i>	<i>SPG7</i>	<i>PLA2G6</i>	<i>PRKN</i>	<i>GCH1</i>	<i>GBA1</i> †	Mutation-negative ‡	P-value
Index cases (N)	2	1	3	1	30	1	2	1	1	26	1	70	431	
Sex (N Female:Male)	1:1	0:1	3:0	1:0	15:15	0:1	2:0	0:1	1:0	10:16	0:1	28:42	185:246	0.269
Age at Diagnosis (mean ± sd) *	44.5 (0.7) d	61-65	63.3 (4.2) d	55-60	59.5 (13.7) d	31-35	44.5 (6.4) d	41-45	36-40	36.4 (8.0) c	36-40	53.9 (12.5) d	55.8 (14.0)	<b>8.52E-09</b>
Age at Assessment (mean ± sd) *	48.5 (0.7) d	66-70	76.0 (5.2) d	55-60	64.5 (11.6) d	36-40	54.5 (0.7) d	46-50	41-45	50.0 (12.3) a	41-45	58.6 (12.2) d	60.6 (13.2)	<b>2.11E-04</b>
Disease duration at assessment (Years, mean ± sd)	8.5 (4.9) d	8	19.7 (7.5) d	1	6.8 (4.9) d	8	18 (11.3) d	25	9	21.6 (14.0) c	9	9.5 (9.8) d	8.4 (8.3)	<b>1.69E-06</b>
Genetically Determined Ancestry (%)														0.367
African	0	0	0	0	0	0	0	0	0	0	0	1.4	0.7	
American	0	0	0	0	0	0	0	0	0	0	0	0	0.7	
Ashkenazi Jewish	0	0	0	0	10	100	0	0	0	0	0	1.4	1.2	
Central Asian	0	0	0	0	0	0	0	0	0	0	0	0	0.5	
East Asian	0	0	0	0	0	0	0	0	0	0	0	0	0.2	
European	100	100	100	100	90	0	50	100	100	100	100	91.4	91.4	
Finnish	0	0	0	0	0	0	0	0	0	0	0	1.4	0	
Middle Eastern	0	0	0	0	0	0	0	0	0	0	0	0	0.5	
South Asian	0	0	0	0	0	0	50	0	0	0	0	2.9	4.4	
Complex Admixture	0	0	0	0	0	0	0	0	0	0	0	0	0.2	
Unknown	0	0	0	0	0	0	0	0	0	0	0	1.4	0.5	
Family history (%)														0.001**
No family history	100	0	0	0	16.7	100	50	0	100	57.7	0	28.6	28.8	
One affected relative	0	0	33.3	0	30	0	50	100	0	30.8	100	40.0	48.0	
Two affected relatives	0	100	33.3	100	26.7	0	0	0	0	7.7	0	20.0	16.0	
Three or more affected relatives	0	0	33.3	0	26.7	0	0	0	0	3.8	0	11.4	7.2	
Self-reported parental consanguinity (%)	0	0	0	0	3.4	0	100	0	0	4.3	0	0	1.3	0.015 **

†Excludes cases not investigated with WGS ( $n=3$ ) and *GBA1* variants that coexist with pathogenic mutations in *LRRK2* ( $n=1$ ), *PRKN* biallelic ( $n=2$ ), *PRKN* monoallelic ( $n=3$ ), *PINK1* monoallelic ( $n=1$ ) and *GCH1* ( $n=1$ ).

‡ Excludes mutation-negative cases not investigated with both WGS and MLPA ( $n=122$ ), carriers of *GBA1* variants and of monoallelic pathogenic *PRKN* and *PINK1* mutations.

\* When  $N = 1$ , Age at Diagnosis and Age at Assessment are presented as a 5-year age bracket.

Continuous variables were tested with Kruskal-Wallis test with FDR-adjusted P-values for multiple comparisons. Categorical variables were tested with Fisher's exact test.

Only genes with  $N \geq 2$  were tested. Significance levels show comparison with mutation-negative group only: a,  $P < 0.05$ . b,  $P < 0.001$ . c,  $P < 0.0001$ . d, not significant. \*\*No significant P-values after FDR-adjusted pairwise comparisons across genes.

**Supplementary Table 8.** Clinical features of *PRKN* single mutation carriers index cases

	<i>PRKN</i> monoallelic vs mutation-negative ‡			<i>PRKN</i> monoallelic vs <i>PRKN</i> biallelic	
	<i>PRKN</i> monoallelic †	Beta (95% CI)	P-value	Beta (95% CI)	P-value
Age at Onset (mean ± sd)	52.2 (15.5)	-2.9 (-10.4, 4.6)	0.449	10.4 (1.1, 19.6)	<b>0.028</b>
Age at Diagnosis (mean ± sd)	54.8 (15.2)	-2.4 (-10.2, 5.3)	0.535	12.0 (2.5, 21.6)	<b>0.013</b>
Age at Assessment (mean ± sd)	57.2 (14.9)	-2.9 (-10.4, 4.6)	0.449	10.4 (1.1, 19.7)	<b>0.028</b>
Disease duration at assessment (Years, mean ± sd)	4.9 (2.6)	-3.3 (-8.3, 1.6)	0.187	-16.6 (-22.5, -10.7)	<b>6.21E-08</b>
MDS-UPDRS Part III (mean ± sd)	19.6 (8.8)	-3.7 (-13.2, 5.8)	0.447	1.0 (-11.6, 13.5)	0.881
Motor Severity Score (mean ± sd)	6.1 (8.4)	0.02 (-4.0, 4.0)	0.992	4.4 (-0.6, 9.4)	0.083
Motor Aspects of Daily Living (mean ± sd)	9.8 (9.1)	2.0 (-6.9, 3)	0.431	7.1 (1.0, 13.1)	<b>0.022</b>
Motor Complications (%)					
Dyskinesias	27.3	0.36 (-1.2, 1.66)	0.610	1.4 (-0.6, 3.4)	0.155
Motor fluctuations	27.3	-0.4 (-2.0, 0.9)	0.548	1.3 (-0.8, 3.3)	0.230
Off dystonia	9.1	-0.9 (-3.8, 0.84)	0.411	0.3 (-2.9, 2.6)	0.822
Autonomic Dysfunction (%)					
Orthostatic Hypotension	45.5	-0.10 (-1.4, 1.1)	0.869	0.8 (-0.7, 2.3)	0.298
Constipation	27.3	-0.8 (-2.4, 0.5)	0.239	0.0 (-1.8, 1.6)	0.995
Urinary Dysfunction	54.5	-0.19 (-1.4, 1.1)	0.756	0.6 (-0.9, 2.2)	0.412
REM Sleep Behaviour Disorder (%)	45.5	0.4 (-0.8, 1.6)	0.483	0.8 (-0.6, 2.3)	0.259
Neuropsychiatric Symptoms (%)					
Apathy	27.3	0.0 (-1.6, 1.2)	0.951	0.8 (-1.1, 2.6)	0.400
Depression	18.2	0.3 (-1.6, 1.7)	0.712	1.2 (-1.1, 3.6)	0.282
Anxiety	27.3	0.4 (-1.1, 1.7)	0.528	0.4 (-1.4, 2.2)	0.620
Dopamine Dysregulation Syndrome	9.1	-0.3 (-3.3, 1.4)	0.752	0.3 (-2.9, 2.6)	0.833
Hallucinations	18.2	0.4 (-1.5, 1.8)	0.606	1.8 (-0.6, 4.2)	0.125
Total MoCA score (mean ± sd)	27.0 (4.4)	0.27 (-1.6, 2.2)	0.778	0.2 (-2.2, 2.7)	0.856

† Excludes cases without both MLPA and WGS. ‡ Excludes mutation-negative cases not investigated with both WGS and MLPA ( $n=122$ ), carriers of *GBA1* variants and of monoallelic pathogenic *PRKN* and *PINK1* mutations. Linear, logistic or multinomial regression as appropriate, after adjustment for sex, age and disease duration (except age at onset, which was adjusted only for sex and disease duration, and motor severity, which was adjusted only for sex and age). Significance level set at <0.05.

**Supplementary Table 9.** Variant details of families carrying a pathogenic or risk variant in *GBA1*

Family ID	Diagnosis	Group	Gene	Variant	Additional variants	Investigations
1	PD	fLOPD	<i>GBA1</i>	D448H		NCA, MLPA, WGS
2	PD	sEOPD	<i>GBA1</i>	G152E	E365K	NCA, MLPA, WGS
3	PD	sEOPD	<i>GBA1</i>	G152A		NCA, MLPA, WGS
4	PD	fEOPD	<i>GBA1</i>	G416S		NCA, MLPA, WGS
5	PD	fLOPD	<i>GBA1</i>	N409S		NCA, MLPA
6	PD	fEOPD	<i>GBA1</i>	N409S	<i>PINK1</i> exon 5 deletion	NCA, MLPA, WGS
	Unaffected	NA	<i>GBA1</i>	N409S		NCA, MLPA
7	Unaffected	NA	-	-	<i>PINK1</i> exon 5 deletion	NCA, MLPA
	PD	fLOPD	<i>GBA1</i>	N409S		NCA, MLPA, WGS
8	PD	fEOPD	<i>GBA1</i>	N409S		NCA, MLPA, WGS
8	Unaffected	NA	<i>GBA1</i>	N409S		NCA
	PD	sEOPD	<i>GBA1</i>	N409S		NCA, MLPA
10	PD	sEOPD	<i>GBA1</i>	P138Lfs*62		WGS
11	PD	sEOPD	<i>GBA1</i>	P138Lfs*62		NCA, MLPA, WGS
12	PD	fLOPD	<i>GBA1</i>	Y244Tfs*10		NCA, MLPA, WGS
13	PD	fEOPD	<i>GBA1</i>	V333Rfs*4		NCA, MLPA, WGS
14	PD	fLOPD	<i>GBA1</i>	A163fs		NCA, MLPA, WGS
15	PD	fEOPD	<i>GBA1</i>	c.1263del		NCA, MLPA, WGS
	PD	fLOPD	<i>GBA1</i>	c.1263del		NCA, MLPA, WGS
16	PD	fEOPD	<i>GBA1</i>	IVS2DS+1G-A		NCA, MLPA, WGS
17	PD	fLOPD	<i>GBA1</i>	P430H		NCA, WGS
18	PD	fLOPD	<i>GBA1</i>	R159Q		NCA, MLPA, WGS
19	PD	fEOPD	<i>GBA1</i>	R159W		NCA, MLPA, WGS
20	PD	fEOPD	<i>GBA1</i>	R296Q	<i>GCH1</i> K224R	NCA, MLPA, WGS
	Unaffected	NA	<i>GBA1</i>	R296Q		NCA
20	Unaffected	NA	<i>GBA1</i>	R296Q		NCA
	PD	fLOPD	<i>GBA1</i>	R398*		NCA, MLPA
22	PD	fLOPD	<i>GBA1</i>	Y352*		NCA, MLPA, WGS
23	PD	fLOPD	<i>GBA1</i>	R502C		NCA, MLPA, WGS
24	PD	fLOPD	<i>GBA1</i>	R502C		NCA, MLPA, WGS
25	PD	fLOPD	<i>GBA1</i>	R502C		NCA, MLPA, WGS
26	PD	sEOPD	<i>GBA1</i>	R502C		NCA, MLPA, WGS
27	PD	fEOPD	<i>GBA1</i>	T362I		NCA, MLPA, WGS
28	PD	fLOPD	<i>GBA1</i>	L29Afs*18	<i>LRK2</i> G2019S	NCA, MLPA, WGS
29	PD	fLOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
30	PD	fLOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
31	PD	fLOPD	<i>GBA1</i>	L483P		NCA, MLPA, WGS
32	PD	fLOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
33	PD	fLOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
34	PD	fLOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
35	PD	fLOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
36	PD	sEOPD	<i>GBA1</i>	L483P		NCA, MLPA, WGS
37	PD	fLOPD	<i>GBA1</i>	T408M	E365K	NCA, MLPA, WGS
	PD	fLOPD	<i>GBA1</i>	T408M	E365K	NCA, MLPA, WGS
38	PD	fEOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
	Unaffected	NA	-	-		NCA, MLPA
39	PD	fLOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
40	PD	sEOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
41	PD	sEOPD	<i>GBA1</i>	L483P		NCA, MLPA, WGS
	Unaffected	NA	-	-		NCA
42	PD	sEOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
	Unaffected	NA	-	-		NCA
42	Unaffected	NA	-	-		NCA
	PD	sEOPD	<i>GBA1</i>	L483P		NCA, MLPA, WGS
44	PD	fEOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
45	PD	fLOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
46	PD	fEOPD	<i>GBA1</i>	T408M		NCA, WGS
47	PD	sEOPD	<i>GBA1</i>	L483P		NCA, MLPA, WGS
48	PD	fEOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
49	PD	sEOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
50	PD	fLOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
51	PD	fLOPD	<i>GBA1</i>	M162T		NCA, MLPA, WGS
52	PD	sEOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
53	PD	sEOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
54	PD	fLOPD	<i>GBA1</i>	L483P		NCA, MLPA, WGS
55	PD	sEOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
56	PD	sEOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
57	PD	fLOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
58	PD	fLOPD	<i>GBA1</i>	L483P		NCA, MLPA, WGS

**Supplementary Table 9.** Variant details of families carrying a pathogenic or risk variant in *GBA1*

Family ID	Diagnosis	Group	Gene	Variant	Additional variants	Investigations
59	PD	fLOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
60	PD	fLOPD	<i>GBA1</i>	L483P		NCA, MLPA, WGS
61	PD	fLOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
62	PD	fEOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
63	PD	fLOPD	<i>GBA1</i>	L483P		NCA, MLPA, WGS
64	PD	fEOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
65	PD	fLOPD	<i>GBA1</i>	L483P		NCA, MLPA, WGS
	Unaffected	NA	-	-		NCA, MLPA
66	PD	sEOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
67	PD	fEOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
	Unaffected	NA	-	-		NCA, MLPA
68	PD	sEOPD	<i>GBA1</i>	P454A		NCA, MLPA, WGS
	Unaffected	NA	-	-		NCA
69	PD	fLOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
70	PD	fEOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
	Unaffected	NA	-	-		NCA, MLPA
71	PD	fLOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
72	PD	fLOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
	PD	fLOPD	<i>GBA1</i>	T408M		NCA, MLPA, WGS
	Unaffected	NA	-	-		NCA, MLPA
73	Unaffected	NA	-	-		NCA, MLPA
	Unaffected	NA	-	-		NCA, MLPA
	Unaffected	NA	-	-		NCA, MLPA
74	PD	fLOPD	<i>GBA1</i>	E365K		NCA, MLPA, WGS
75	PD	sEOPD	<i>GBA1</i>	L483P		MLPA, WGS
76	PD	sEOPD	<i>GBA1</i>	E365K		MLPA, WGS
77	PD	fLOPD	<i>GBA1</i>	T408M	<i>PRKN</i> R275W	NCA, MLPA, WGS
78	PD	fLOPD	<i>GBA1</i>	E365K	<i>PRKN</i> K211N	NCA, MLPA, WGS
79	PD	sEOPD	<i>GBA1</i>	L483P	<i>PRKN</i> exon 1 deletion	NCA, MLPA, WGS
80	PD	sEOPD	<i>GBA1</i>	T408M	<i>PRKN</i> G248R	NCA, WGS
81	PD	sEOPD	<i>GBA1</i>	T408M	<i>PRKN</i> exons 3-4 deletion	NCA, MLPA, WGS

AAO = Age at onset, AAC = age at consent, NCA = NeuroChip array, MLPA = Multiplex ligation-dependent probe amplification, WGS = whole-genome sequencing, AJ = Ashkenazi Jewish, EUR = European, SAS = South Asian, FIN = Finnish, AFR = African, NA = Not applicable.

**Supplementary Table 10.** Clinical features of *GBA1* mutation-carriers vs mutation-negative by variant severity in index cases

	Risk	Mild	Severe	Mutation-negative ‡	P-value		
	N = 34	(N = 3)	(N = 22)	N = 431	Risk	Mild	Severe
Age at Onset (mean ± sd)	51.6 (16.2)	44.3 (16.0)	47.4 (13.9)	52.3 (15.0)	0.884	0.625	0.337
Motor Features (mean ± sd)							
MDS-UPDRS Part III	25.2 (13.2)	39.0 (11.3)	27.5 (17.9)	26.5 (17.4)	0.696	0.484	0.672
Motor Severity Score	6.6 (6.0)	4.7 (4.4)	6.1 (6.7)	6.3 (6.7)	0.788	0.726	0.814
Motor Subtype (%)							
Tremor-dominant	28.6	0	30.8	39.1			
PIGD-dominant	61.9	100	61.5	52.1	0.451	NA	0.524
Intermediate	9.5	0	7.7	8.8	0.659	NA	0.901
Hoehn and Yahr stage (%)							
0-1.5	45.8	0	7.7	38.2			
2 or 2.5	29.2	0	61.5	37.8	0.346	NA	0.075
3+	25	100	30.8	24	0.583	NA	0.149
Motor Complications (%)							
Dyskinesias	26.1	50	23.1	26	0.729	0.808	0.415
Motor fluctuations	45.5	100	25	43.4	0.920	0.985	<b>0.048</b>
Off dystonia	19	100	14.3	24	0.484	0.985	0.159
Motor Aspects of Daily Living (mean ± sd)	13.2 (8.9)	19.3 (14.0)	12.7 (7.6)	13.5 (9.2)	0.714	0.459	0.248
Autonomic Dysfunction (%)							
Orthostatic Hypotension	35.5	66.7	47.6	48.6	0.154	0.708	0.907
Constipation	68.8	66.7	57.1	49.1	<b>0.034</b>	0.644	0.385
Urinary Dysfunction	64.5	66.7	61.9	64.2	0.932	0.995	0.813
REM Sleep Behaviour Disorder (%)	50	66.7	52.4	39.9			
Neuropsychiatric Symptoms (%)							
Apathy	12.5	50	40	30.7	0.055	0.727	0.543
Depression	0	50	18.8	14.8	0.984	0.318	0.918
Anxiety	8.3	50	18.8	20.8	0.141	0.446	0.625
Dopamine Dysregulation Syndrome	4.3	50	31.2	13.2	0.205	0.266	0.125
Hallucinations	12.5	50	31.2	15.5	0.603	0.395	0.242
MoCA score (mean ± sd)	26.3 (2.8)	24.5 (3.5)	24.7 (3.1)	26.3 (3.4)	0.847	0.477	<b>0.039</b>

Excludes *GBA1* variants of unknown severity ( $n=9$ ), *GBA1* mutations that coexist with pathogenic mutations in other PD-related genes ( $n=8$ ), individuals not investigated with WGS ( $n=3$ ) and individuals who are compound heterozygous for *GBA1* variants ( $n=2$ ). ‡ Excludes mutation-negative cases not investigated with both WGS and MLPA ( $n=122$ ), carriers of *GBA1* variants and of monoallelic pathogenic *PRKN* and *PINK1* mutations. Linear, logistic or multinomial regression were used as appropriate, after adjustment for sex, age and disease duration (except age at onset, which was adjusted only for sex and disease duration, and motor severity, which was adjusted only for sex and age). Significance level set at  $<0.05$ . MDS-UPDRS items were used to define the following clinical features: dyskinesias (items 4.1+4.2  $>0$ ); motor fluctuations (items 4.3+4.4+4.5  $>0$ ); off-dystonia (item 4.6  $>0$ ); orthostatic hypotension (item 1.12  $>0$ ); constipation (item 1.11  $>0$ ); urinary dysfunction (item 1.10  $>0$ ); apathy (item 1.5  $>0$ ); depression (item 1.3  $>1$ ); anxiety (item 1.4  $>1$ ); impulse control disorder (item 1.6  $>0$ ); hallucinations (item 1.2  $>0$  and  $<4$ ). Motor severity scores are MDS-UPDRD part III scores divided by disease duration in years. Motor subtypes were defined according to Stebbins et al., 2013. Motor aspects of daily living scores are the sum of MDS-UPDRS part II items. REM sleep behaviour disorder was defined as RBDSQ score  $>5$ . NA=not applicable.

**Supplementary Table 11. GP2 gene panel**

Gene	Ensembl gene ID	MANE Select
AFG3L2	ENSG00000141385	NM_006796.3
ATP13A2	ENSG00000159363	NM_022089.4
ATP1A3	ENSG00000105409	NM_152296.5
ATP6AP2	ENSG00000182220	NM_005765.3
ATP7B	ENSG00000123191	NM_000053.4
C19orf12	ENSG00000131943	NM_031448.6
CHCHD10	ENSG00000250479	NM_213720.3
CHCHD2	ENSG00000106153	NM_016139.4
COASY	ENSG00000068120	NM_025233.7
CP	ENSG00000047457	NM_000096.4
CSF1R	ENSG00000182578	NM_001288705.3
DCAF17	ENSG00000115827	NM_025000.4
DCTN1	ENSG00000204843	NM_004082.5
DNAJC12	ENSG00000108176	NM_021800.3
DNAJC6	ENSG00000116675	NM_001256864.2
EPM2A	ENSG00000112425	NM_005670.4
FA2H	ENSG00000103089	NM_024306.5
FBXO7	ENSG00000100225	NM_012179.4
FTL	ENSG00000087086	NM_000146.4
GBA1	ENSG00000177628	NM_000157.4
GCH1	ENSG00000131979	NM_000161.3
GLB1	ENSG00000170266	NM_000404.4
GRN	ENSG00000030582	NM_002087.4
JAM2	ENSG00000154721	NM_021219.4
LRRK2	ENSG00000188906	NM_198578.4
LYST	ENSG00000143669	NM_000081.4
MAPT	ENSG00000186868	NM_001377265.1
MYORG	ENSG00000164976	NM_020702.5
NPC1	ENSG00000141458	NM_000271.5
NPC2	ENSG00000119655	NM_006432.5
NR4A2	ENSG00000153234	NM_006186.4
OPA1	ENSG00000198836	NM_130837.3
OPA3	ENSG00000125741	NM_025136.4
PANK2	ENSG00000125779	NM_001386393.1
PARK7	ENSG00000116288	NM_007262.5
PDE8B	ENSG00000113231	NM_003719.5
PDGFB	ENSG00000100311	NM_002608.4
PDGFRB	ENSG00000113721	NM_002609.4
PINK1	ENSG00000158828	NM_032409.3
PLA2G6	ENSG00000184381	NM_003560.4
POLG	ENSG00000140521	NM_002693.3
PRKN	ENSG00000185345	NM_004562.3
PRKRA	ENSG00000180228	NM_003690.5
PTRHD1	ENSG00000184924	NM_001013663.2
PTS	ENSG00000150787	NM_000317.3
QDPR	ENSG00000151552	NM_000320.3
RAB39B	ENSG00000155961	NM_171998.4
SCP2	ENSG00000116171	NM_002979.5
SLC20A2	ENSG00000168575	NM_001257180.2
SLC25A4	ENSG00000151729	NM_001151.4
SLC25A46	ENSG00000164209	NM_138773.4
SLC30A10	ENSG00000196660	NM_018713.3
SLC39A14	ENSG00000104635	NM_001128431.4
SLC6A3	ENSG00000142319	NM_001044.5
SMPD1	ENSG00000166311	NM_000543.5
SNCA	ENSG00000145335	NM_000345.4
SPG11	ENSG00000104133	NM_025137.4
SPG7	ENSG00000197912	NM_003119.4
SPR	ENSG00000116096	NM_003124.5



**Supplementary Table 11. GP2 gene panel**

Gene	Ensembl gene ID	MANE Select
SQSTM1	ENSG00000161011	NM_003900.5
SYNJ1	ENSG00000159082	NM_203446.3
TAF1	ENSG00000147133	NM_004606.5
TBK1	ENSG00000183735	NM_013254.4
TH	ENSG00000180176	NM_000360.4
TUBB4A	ENSG00000104833	NM_006087.4
TWINK	ENSG00000107815	NM_021830.5
VAC14	ENSG00000103043	NM_018052.5
VCP	ENSG00000165280	NM_007126.5
VPS13A	ENSG00000197969	NM_033305.3
VPS13C	ENSG00000129003	NM_020821.3
VPS35	ENSG00000069329	NM_018206.6
WDR45	ENSG00000196998	NM_001029896.2
XPR1	ENSG00000143324	NM_004736.4
ZFYVE26	ENSG00000072121	NM_015346.4

**Supplementary Table 12.** Primer Sequences

	<b>Forward (5' – 3')</b>	<b>Reverse (5' – 3')</b>
<b><i>ATXN2</i></b>	6-FAM-TTTCGGCGGCTCCTTGGTCTC	AGCCGCGGGCGGCGGCTGCTGCTGCTGCTG
<b><i>ATXN3</i></b>	6-FAM-AGTCCAGTGACTACTTTGATTCG	GTCCTGATAGGTCCCCTGCTGCTGCTGCTG

## **PPF Study Group**

**Lead Investigators:** Prof Huw R. Morris (UCL Queen Square Institute of Neurology), Dr Paul R. Jarman (National Hospital for Neurology and Neurosurgery), Prof Henry Houlden (UCL Queen Square Institute of Neurology), Prof Nicholas W. Wood (UCL Queen Square Institute of Neurology), Dr Raquel Real (UCL Queen Square Institute of Neurology)

**Co-Investigators:** Manuela Tan (UCL Queen Square Institute of Neurology), Russel Tilney (UCL Queen Square Institute of Neurology)

**Principal investigators for sites:** Huw R. Morris (Royal Free London NHS Trust and University College London Hospitals NHS Foundation Trust), Elizabeth Wakeman (Isle of Wight NHS Trust), Tabish Saifee (London North West Healthcare NHS Trust), Sam Arianayagam (Hampshire Hospitals NHS Foundation Trust), Saifuddin Shaik (Lancashire Teaching Hospitals NHS Trust), Sophie Molloy (Imperial College Healthcare NHS Trust and London North West Healthcare NHS Trust), Ralph Gregory (University Hospitals Dorset NHS Foundation Trust), Mirdhu Wickremaratchi (Western Sussex Hospitals NHS Foundation Trust), Rosaria Buccoliero (Harrogate and District NHS Foundation Trust), Oliver Bandmann (Sheffield Teaching Hospital NHS Foundation Trust), Dominic Paviour (St George's University Hospitals NHS Foundation Trust), Diran Padiachy (Salisbury NHS Foundation Trust), Anjum Misbahuddin (Barking, Havering and Redbridge University Hospitals NHS Trust), Jeremy Cosgrove (Leeds Teaching Hospitals NHS Trust), Sunku Guptha (North West Anglia NHS Foundation Trust), Ray Chaudhuri (King's College Hospital NHS Foundation Trust), Yen Tai (The Hillingdon Hospitals NHS Foundation Trust), Sukaina Asad (University Hospitals of Leicester NHS Trust), Ayano Funaki (Central London Community Healthcare NHS Trust), Marek Kunc (Airedale NHS Foundation Trust), Charlotte Brierley (West Suffolk NHS Foundation Trust), Ray Sheridan (Royal Devon & Exeter NHS Foundation Trust), Rena Truscott (Livewell Southwest), Suzanne Dean (Royal Cornwall Hospitals NHS Trust), Carinna Vickers (Somerset NHS Foundation Trust), Rani Sophia (Yeovil District Hospital NHS Foundation Trust), Sion Jones (Betsi Cadwaladr University Health Board), Erica Capps (The Shrewsbury and Telford Hospital NHS Trust), Neil Archibald (South Tees Hospitals NHS Foundation Trust), Louise Wiblin (South Tees Hospitals NHS Foundation Trust), Sean J Slaght (Portsmouth Hospitals NHS Trust), Edward Jones (York Teaching Hospital NHS Foundation Trust), Colin Barnes (Solent NHS Trust), Dominick D'Costa (The Royal Wolverhampton NHS Trust), Carl Mann (Midlands Partnership NHS Foundation Trust), Uma Nath (South Tyneside and Sunderland NHS Foundation Trust), Anette Schrag (Bedfordshire Hospitals NHS Foundation Trust), Sarah Williams (St Helens and Knowsley Teaching Hospitals NHS Trust), Gillian Webster (North Cumbria Integrated Care NHS Foundation Trust), Sigurlaug Sveinbjornsdottir (Mid and South Essex NHS Foundation Trust), Lucy Strens (University Hospitals Coventry & Warwickshire), Annette Hand (Northumbria Healthcare NHS Foundation Trust), Richard Walker (Northumbria Healthcare NHS Foundation Trust), Rosemary Crouch (Birmingham Community Healthcare NHS Trust), Jason Raw (Northern Care Alliance NHS Foundation Trust), Stephanie Tuck (Norfolk Community Health & Care NHS Trust), Khaled Amar (University Hospital Dorset NHS Foundation Trust), Emma Wales (Wye Valley NHS Trust), Irene Gentilini (Cambridge University Hospitals NHS

Foundation Trust), Aileen Nacorda (Cambridge University Hospitals NHS Foundation Trust), Louise Hartley (Barts Health NHS Trust)

**Clinical research assistants and support staff for sites:** Simona Jasaityte (Royal Free London NHS Trust and University College London Hospitals NHS Foundation Trust, Research Assistant), Miriam Pollard (Royal Free London NHS Trust and University College London Hospitals NHS Foundation Trust, Research Assistant), Megan Hodgson (University College London Hospitals NHS Foundation Trust, Research Assistant), Clodagh Towns (Royal Free London NHS Trust and University College London Hospitals NHS Foundation Trust, Research Assistant), Matilda Fenn (Royal Free London NHS Trust and University College London Hospitals NHS Foundation Trust, Research Assistant), Sarah Cable (Royal Free London NHS Trust and University College London Hospitals NHS Foundation Trust, Research Assistant), Kaylee Gauntlett (Isle of Wight NHS Trust), Deborah Dellafera (Hampshire Hospitals NHS Foundation Trust, Senior Research Nurse), Vicki Fleming (Lancashire Teaching Hospitals NHS Trust, Research Nurse), Judith Dube (University Hospitals Dorset NHS Foundation Trust, Research Nurse), Sarah House (Western Sussex Hospitals NHS Foundation Trust, Clinical Research Practitioner), Caroline Bennett (Harrogate and District NHS Foundation Trust), Helen Casbolt (Sheffield Teaching Hospital NHS Foundation Trust, Clinical Trials Assistant), James Lee (Salisbury NHS Foundation Trust), Laura Parker-Wall (Barking, Havering and Redbridge University Hospitals NHS Trust, Research Nurse), Prisca Mpofu (Leeds Teaching Hospitals NHS Trust, Research Nurse), Dhaval Trivedi (King's College Hospital NHS Foundation Trust), Sofiya Portukhay (The Hillingdon Hospitals NHS Foundation Trust, Clinical Trials Coordinator), Rehanah Roopun (University Hospitals of Leicester NHS Trust, Research Nurse), Lisa Armstrong (Airedale NHS Foundation Trust, Clinical Trials Coordinator), Clare O'Reilly (Royal Devon & Exeter NHS Foundation Trust, Senior Research Nurse), Jonathan Gilby (Livewell Southwest, Senior Research Practitioner), Nishi Singh (Somerset NHS Foundation Trust, Research Nurse), Alison Lewis (Yeovil District Hospital NHS Foundation Trust, research nurse), Julia Roberts (Betsi Cadwaladr University Health Board), Claire Watkins (Betsi Cadwaladr University Health Board), Hannah Gibson (The Shrewsbury and Telford Hospital NHS Trust, Assistant Research Practitioner), Jo Stickley (The Shrewsbury and Telford Hospital NHS Trust, Research Nurse), Catherine Edwards (Portsmouth Hospitals NHS Trust, PD Nurse Specialist), Kerry Elliott (York Teaching Hospital NHS Foundation Trust, Research Nurse), Emma Searle (Solent NHS Trust, Research Nurse), Blessing Okoko (The Royal Wolverhampton NHS Trust, Research Nurse), Susan Wilson (South Tyneside and Sunderland NHS Foundation Trust, Research Nurse), Yvonne Croucher (Bedfordshire Hospitals NHS Foundation Trust), Sharon Dealing (St Helens and Knowsley Teaching Hospitals NHS Trust, Research Nurse), Hannah Martin (University Hospitals Coventry & Warwickshire, Advanced Nurse Practitioner), Claire Williams (Birmingham Community Healthcare NHS Trust, Research Nurse), Lucy Booth (Birmingham Community Healthcare NHS Trust, Research Nurse), Steph Howard (Norfolk Community Health & Care NHS Trust), Rochelle Hernandez (University Hospital Dorset NHS Foundation Trust, Research Nurse), Sue Anderson (Wye Valley NHS Trust, Clinical Trials Nurse), Nosheen Khalid (Barts Health NHS Trust, Clinical Trial Practitioner)

## GP2 Consortium

Affiliation	Contributor
Centre Hospitalo-Universitaire Dr Benbadis Constantine, Constantine, Algeria	Yasser Mecheri
Sanatorio de la Trinidad Mitre- INEBA, Buenos Aires, Argentina	Emilia M Gatto
Hospital JM Ramos Mejia, Buenos Aires, Argentina	Marcelo Kauffman
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina	Federico Capparelli
Somnus Neurology Clinic, Yerevan, Armenia	Samson Khachatryan, Zaruhi Tavadyan, Mariam Isayan
Neuroscience Research Australia, Sydney, New South Wales, Australia	Claire E Shepherd, Simon Rowe, Dennis Yeow Carolyn Sue
ANZAC Research Institute, Concord, New South Wales, Australia	Julie Hunter
Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia	Kishore Kumar
Concord Hospital, Concord, New South Wales, Australia	Melina Ellis, Kishore Kumar
QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia	Miguel E. Rentería, Victor Flores Ocampo
Murdoch University, Perth, Western Australia, Australia	Sulev Koks
Medical University Vienna Austria, Vienna, Austria	Alexander Zimprich
Istanbul Klinik, Baku, Azerbaijan	Kanan Jafarov
University of Antwerp, Antwerp, Belgium	David Crosiers
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil	Artur F. Schumacher-Schuh, Paula Saffie Awad,
Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil	Artur F. Schumacher-Schuh
Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil	Carlos Rieder
University of São Paulo, São Paulo, Brazil	Vitor Tumas
Universidade Federal de Minas Gerais , Belo Horizonte, Brazil	Sarah Camargos, Lucas Faria Costa
Montreal Neurological Institute, Montreal, Quebec, Canada	Edward A. Fon
Institut universitaire de gériatrie de Montréal , Montreal, Quebec, Canada	Oury Monchi
McGill University, Montreal, Quebec, Canada	Ted Fon, Ziv Gan-Or, Konstantin Senkevich
Aligning Science Across Parkinson's, Vancouver, British Columbia, Canada	Robert Thibault, Devin Sharp
University of Toronto, Toronto, Ontario, Canada	Anthony Lang
Universidad de Chile, Santiago, Chile	Benjamin Pizarro Galleguillos, Patricio Olguin, Maria Leonor Bustamante
Fundación Diagnosis, Santiago, Chile	Marcelo Miranda
CETRAM, Santiago, Chile	Pedro Chana
Hospital Regional de Concepción, Concepcion, Chile	Elias Fernandez
Central South University, Changsha, China	Beisha Tang, Zhenhua Liu
West China Hospital Sichuan University, Chengdu, China	Huifang Shang
Xiangya Hospital, Changsha, China	Zhenhua Liu, Jifeng Guo
Capital Medical University, Beijing, China	Piu Chan
Zhejiang University, Hangzhou, China	Wei Luo
Universidad Nacional de Colombia, Bogotá, Colombia	Gonzalo Arboleda

<b>Affiliation</b>	<b>Contributor</b>
Fundación Valle del Lili, Santiago De Cali, Colombia	Jorge Orozco
University of Antioquia, Medellín, Colombia	Marlene Jimenez del Rio
University of Costa Rica, San Jose, Costa Rica	Alvaro Hernandez
Aarhus University, Aarhus, Denmark	Per Borghammer
The American University in Cairo, Cairo, Egypt	Mohamed Salama
Beni-Suef University, Beni Suef, Egypt	Walaa A. Kamel
Addis Ababa University, Addis Ababa, Ethiopia	Yared Z. Zewde
Paris Brain Institute, Paris, France	Alexis Brice
Sorbonne Université, Paris, France	Jean-Christophe Corvol, Mari Vidailhet
Salpêtrière Hospital (AP-HP), Paris, France	Mari Vidailhet
Tbilisi State Medical University, Tbilisi, Georgia	Mariam Kekenadze
S. Khechinashvili University Hospital, Tbilisi, Georgia	Irine Khatiashvili
University of Lübeck, Lübeck, Germany	Ana Westenberger, Christine Klein, Eva-Juliane Vollstedt, Harutyun Madoev, Joanne Trinh, Johanna Junker, Katja Lohmann, Theresa Luth, Inke König, Lara M. Lange
University Medical Center Göttingen, Göttingen, Germany	Brit Mollenhauer
Department of Neurology, University Hospital, LMU Munich, Munich, Germany	Franziska Hopfner, Günter Höglinger
University Medical Center Schleswig-Holstein, Lübeck, Germany	Lara M. Lange, Daniela Berg
University of Tübingen, Tübingen, Germany	Manu Sharma, Thomas Gasser, Wenhua Sun
University of Mainz, Mainz, Germany	Sergiu Groppa
The German Center for Neurodegenerative Diseases, Tübingen, Germany	Zih-Hua Fang, Anastasia Illarionova
Charité - Universitätsmedizin Berlin, Berlin, Germany	Karl Heilbron
Technical University of Munich, Munich, Germany	Bernhard Haslinger
University of Ghana Medical School, Accra, Ghana	Albert Akpalu
University of Thessaly, Volos, Greece	Georgia Xiromerisiou, Georgios Hadjigorgiou, Efthymios Dadiotis
Aristotle University of Thessaloniki, Thessaloniki, Greece	Ioannis Dagklis
Ionian University, Corfu, Greece	Ioannis Tarnanas
Biomedical research Foundation of the Academy of Athens, Athens, Greece	Leonidas Stefanis
Diagnostic and Therapeutic Centre HYGEIA Hospital, Marousi, Greece	Maria Stamelou
Hospital San Felipe, Tegucigalpa, Honduras	Alex Medina
Queen Elizabeth Hospital , Kowloon, Hong Kong	Germaine Hiu-Fai Chan, Nelson Yuk-Fai Cheung
The Hong Kong University of Science and Technology, Kowloon, Hong Kong	Nancy Ip, Phillip Chan , Xiaopu Zhou
Aster Medcity, Kochi, India	Asha Kishore
Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, India	Divya KP
National Institute of Mental Health & Neurosciences, Bengaluru, India	Pramod Pal
Manipal Hospital, Delhi, India	Prashanth Lingappa Kukkle

<b>Affiliation</b>	<b>Contributor</b>
All India Institute of Medical Sciences, Delhi, India	Roopa Rajan
Nizam's Institute Of Medical Sciences, Hyderabad, India	Rupam Borgohain
Shahid Beheshti University of Medical Science, Tehran, Iran	Mehri Salari
Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel	Tamara Shiner, Avner Thaler
Magna Græcia University of Catanzaro, Catanzaro, Italy	Andrea Quattrone, Monica Gagliardi
University of Pavia, Pavia, Italy	Enza Maria Valente
National Research Council, Cosenza, Italy	Grazia Annesi
University of Perugia, Perugia, Italy	Lucilla Parnetti
University of Rome Tor Vergata, Rome, Italy	Tommaso Schirinzi
IRCCS Mondino Foundation, Pavia, Italy	Caterina Galandra
University of Naples Federico II, Naples, Italy	Anna De Rosa
Juntendo University, Tokyo, Japan	Manabu Funayama, Nobutaka Hattori
Jikei University School of Medicine, Tokyo, Japan	Tomotaka Shiraishi
Institute of Neurology and Neurorehabilitation, Almaty, Kazakhstan	Altynay Karimova, Gulnaz Kaishibayeva
West Kazakhstan Marat Ospanov State Medical University, Aktobe, Kazakhstan	Aigerim Utegenova, Aigul Yemagambetova
Medline Medical Center, Astana, Kazakhstan	Vadim Akhmetzhanov
National Center for Neurosurgery, Astana, Kazakhstan	Seitzhan Aidarov
Astana Medical University, Astana, Kazakhstan	Tautanova Raushan, Dinara Alzhanova
City multi-field hospital No. 1, Astana, Kazakhstan	Bagyzhan Syzdykova Syzdykova
International University of Postgraduate Education, Almaty, Kazakhstan	Zhanybek Myrzayev
South Kazakhstan Medical Academy, Shymkent, Kazakhstan	Saltanat Abdraimova
Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan	Cholpon Shambetova
University of Luxembourg, Esch-sur-Alzette, Luxembourg	Rejko Krüger, Patrick May
University of Malaya, Kuala Lumpur, Malaysia	Ai Huey Tan, Azlina Ahmad-Annuar, Shen-Yang Lim, Yi Wen Tay, Azalea Tenerife Pajo
Universiti Kebangsaan Malaysia, Selangor, Malaysia	Mohamed Ibrahim Norlinah
UKM Medical Molecular Biology Institute, Kuala Lumpur, Malaysia	Nor Azian Abdul Murad
Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia	Shahrul Azmin
International Islamic University, Kuala Lumpur, Malaysia	Wael Mohamed
Tecnologico de Monterrey, Monterrey, Mexico	Daniel Martinez-Ramirez
Instituto Nacional de Neurologia y Neurocirugia, Mexico City, Mexico	Mayela Rodriguez-Violante, Nancy Monroy Jaramillo
Universidad Nacional Autónoma de México, Santiago de Querétaro, Mexico	Paula Reyes-Pérez, Alejandra Medina Rivera
Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia	Bayasgalan Tserensodnom
Tribhuvan University, Kirtipur, Nepal	Rajeev Ojha
Vanderbilt University Medical Center, Amsterdam, Netherlands	Wilma Van De Berg
Radboud University, Nijmegen, Netherlands	Bas Bleom, Bart Van de Warrenburg

<b>Affiliation</b>	<b>Contributor</b>
Brain Research and Innovation Center, Amsterdam, Netherlands	Lisette Charbonnier
University of Otago, Dunedin, New Zealand	Tim J. Anderson, Toni L. Pitcher
University of Lagos, Lagos, Nigeria	Arinola Sanyaolu, Njideka Okubadejo, Oluwadamilola Ojo
University of Calabar Teaching Hospital, Calabar, Nigeria	SIMON IZUCHUKWU OZOMMA
University of Ilorin, Ilorin, Nigeria	Kolawole Wahab
Oslo University Hospital, Oslo, Norway	Lasse Pihlstrøm, Manuela Tan, Ingeborg Haugesag Lie
Stavanger University Hospital, Stavanger, Norway	Jodi Maple-Grødem
University of Science and Technology Bannu, Bannu, Pakistan	Shoaib Ur-Rehman
Universidad Científica del Sur, Lima, Peru	Mario Cornejo-Olivas
Metropolitan Medical Center, Manila, Philippines	Maria Leila Doquenia, Raymond Rosales
University of Puerto Rico, San Juan, Puerto Rico	Angel Vinuela
Research Center of Neurology, Moscow, Russia	Elena Iakovenko
Ufa Federal Research Center, Ufa, Russia	Anna Gareeva
Ufa Scientific Center, Ufa, Russia	Gulnara Akhmadeeva
Bashkir State Medical University, Ufa, Russia	Irina Gilyazova
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia	Bashayer Al Mubarak
King Abdullah International Medical Research Center, Jeddah, Saudi Arabia	Muhammad Umair
National Neuroscience Institute , Singapore, Singapore	Eng-King Tan
Nanyang Technological University, Singapore, Singapore	Jia Nee Foo, Elaine Chew
Ljubljana University Medical Centre, Ljubljana, Slovenia	Vesna van Midden
University of KwaZulu-Natal, Durban, South Africa	Ferzana Amod
University of Stellenbosch, Stellenbosch, South Africa	Jonathan Carr, Soraya Bardien, Kathryn Step
University of the Western Cape, Bellville, South Africa	Nikita Pillay
Seoul National University Hospital, Seoul, South Korea	Beomseok Jeon
Yongin Severance Hospital, Seoul, South Korea	Yun Joong Kim
Seoul National University, Seoul, South Korea	Jung Hwan Shin, Joowon Jang
Hospital Universitario Burgos, Burgos, Spain	Esther Cubo
University Hospital Mutua Terrassa, Barcelona, Spain	Ignacio Alvarez
Institut de Recerca Sant Joan de Deu, Barcelona, Spain	Janet Hoenicka
Research Institute Germans Trias i Pujol, Barcelona, Spain	Katrin Beyer
Instituto de Biomedicina de Sevilla, Seville, Spain	Maria Teresa Periñan, Pilar Gómez Garre, Pablo Mir
University Hospital Germans Trias i Pujol, Barcelona, Spain	Pau Pastor
Hospital Clínic de Barcelona, Barcelona, Spain	Ruben Fernandez-Santiago
Faculty of medicine university of Khartoum , Khartoum, Sudan	Sarah El-Sadig
Lund University, Lund, Sweden	Kajsa Brodin, Maria Swanberg
Karolinska Institute, Stockholm, Sweden	Per Svenningsson



<b>Affiliation</b>	<b>Contributor</b>
Inselspital Bern, University of Bern, Bern, Switzerland	Christiane Zweier, Gerd Tinkhauser, Paul Krack
National Taiwan University Hospital, Taipei City, Taiwan	Chin-Hsien Lin, Ruey-Meei Wu
Chang Gung Memorial Hospital, Taoyuan City, Taiwan	Hsiu-Chuan Wu
National Taiwan University, Taipei City, Taiwan	Pin-Jui Kung
Chang Gung Memorial Hospital, Taoyuan City, Taiwan	Yihru Wu
Avicenna Tajik State Medical University, Dushanbe, Tajikistan	Ganieva Manizha
National Institute Mongi Ben Hamida of Neurology, Tunis, Tunisia	Rim Amouri
Mongi Ben Hmida National Institute of Neurology, Tunis, Tunisia	Samia Ben Sassi
Koç University, Istanbul, Turkey	A. Nazlı Başak, Özgür Öztop Çakmak, Sibel Ertan
Şişli Etfal Training and Research Hospital, Istanbul, Turkey	Gencer Genc
Queen Mary University of London, London, United Kingdom	Alastair Noyce, Sumit Dey, Spencer Finch
University College London, London, United Kingdom	Alejandro Martínez-Carrasco, Anette Schrag, Anthony Schapira, Eleanor J. Stafford, Henry Houlden, Huw R Morris, John Hardy, Kin Ying Mok, Kin Ying Mok, Mie Rizig, Nicholas Wood, Olaitan Okunoye, Rauan Kaiyrzhanov, Rimona Weil, Simona Jasaityte, Vida Obese, Mina Ryten, Thomas Warner, Raquel Real
University of Plymouth, Plymouth, United Kingdom	Camille Carroll
Parkinson's UK, London, United Kingdom	Claire Bale
University of Glasgow, Glasgow, United Kingdom	Donald Grosset
Cardiff University, Cardiff, United Kingdom	Nigel Williams, Valentina Escott-Price
Royal Veterinary College University of London, London, United Kingdom	Patrick Alfryn Lewis
University of Bristol, Bristol, United Kingdom	Seth Love
Cure Parkinson's, London, United Kingdom	Simon Stott
St George's, University of London, London, United Kingdom	Hamin Lee
University of Cambridge, Cambridge, United Kingdom	Roger Barker, Caroline Williams-Gray
University of Oxford, Oxford, United Kingdom	Michele Hu, Laura Parkkinen
Northumbria Healthcare at NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom	Richard Walker
Imperial College London, London, United Kingdom	Steve Gentleman, Christian Lambert, Yen Tai
Newcastle University, Newcastle-upon-Tyne, United Kingdom	David Burn, Chris Morris
YLD, London, United Kingdom	Deborah Attuah
University of Cincinnati, Cincinnati, OH, USA	Alberto Espay, Luca Marsili
The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA	Alyssa O'Grady, Bernadette Siddiqi, Bradford Casey, Brian Fiske, Charisse Comart, Justin C. Solle, Kaileigh Murphy, Maggie Kuhl, Naomi Louie, Sohini Chowdhury, Todd Sherer, Ryan Pflugst, Debi Brooks, Zach Chaney, Conor Hennessey, Cassandra Barrett

Affiliation	Contributor
National Institute on Aging, Bethesda, MD, USA Augusta University / University of Georgia Medical Partnership, Augusta, GA, USA Mid-Atlantic Permanente Medical Group, Bethesda, MD, USA Washington University, St. Louis, MO, USA National Institutes of Health, Bethesda, MD, USA	Andrew B Singleton, Hampton Leonard, Kate Andersh, Laurel Screven, Kensuke Daida Andrew K. Sobering Cabell Jonas Carlos Cruchaga, Laura Ibanez Caroline B. Pantazis, Cornelis Blauwendraat, Dan Vitale, Dena Hernandez, Faraz Faghri, Hampton Leonard, Jonggeol Jeff Kim, Mary B Makarios, Mathew Koretsky, Mike A. Nalls, Sara Bandres-Ciga, Yeajin Song, Spencer Grant, Shannon Ballard, Mark Cookson, Christine Swanson-Fischer
Indiana University, Bloomington, IN, USA Rush University, Chicago, IL, USA Kaiser Permanente, Oakland, CA, USA Banner Sun Health Research Institute, Sun City, AZ, USA Data Tecnica International, Washington, WA, USA Michigan State University, East Lansing, MI, USA Cleveland Clinic, Cleveland, OH, USA Kaiser Permanente, Oakland, CA, USA Baylor College of Medicine, Houston, TX, USA Texas Children's Hospital, Houston, TX, USA Parkinson's Foundation, Princeton, NJ, USA University of Miami Miller School of Medicine, Miami, FL, USA Beth Israel Deaconess Medical Center, Boston, MA, USA North Shore University Health System, Chicago, IL, USA Institute for Neurodegenerative Disorders, New Haven, CT, USA University of Pittsburgh, Pittsburgh, PA, USA University of Alabama at Birmingham, Birmingham, AL, USA University of Maryland, Baltimore, MD, USA University of Florida, Gainesville, FL, USA Northwestern University, Chicago, IL, USA Northwestern University, Evanston, IL, USA Universit of Michigan, Ann Arbor, MI, USA Columbia University , New York, NY, USA James J. Peters Veterans Affairs Medical Center, New York, NY, USA Aligning Science Across Parkinson's, Washington, WA, USA University of Chicago, Chicago, IL, USA	Claire Wegel Deborah Hall Ejaz Shiamim Geidy E. Serrano Hirotaka Iwaki, Kristin S. Levine Honglei Chen Ignacio F. Mata, Miguel Inca-Martinez, James B Leverenz Jared Williamson Joseph Jankovic, Joshua Shulman, Chad Shaw Joshua Shulman Kamalini Ghosh Galvelis Karen Nuytemans Karl Kiebertz Katerina Markopoulou Kenneth Marek Lana M. Chahine Lauren Ruffrage, Marissa Dean, Haydeh Payami Lisa Shulman Matthew Farrer, Ashley Rawls Megan J. Puckelwartz, Steven Lubbe Niccolò Emanuele Mencacci, Ignacio Juan Keller Sarmiento Roger Albin Roy Alcalay Ruth Walker Sonya Dumanis, Ekemini Riley Tao Xie

<b>Affiliation</b>	<b>Contributor</b>
Indiana University School of Medicine, Indianapolis, IN, USA	Tatiana Foroud
Sun Health Research Institution, Sun City, AZ, USA	Thomas Beach
Aligning Science Across Parkinson's, Baltimore, MD, USA	Dana Lewis
Gladstone Institutes, San Francisco, CA, USA	Shreya Menon
Icahn School of Medicine at Mount Sinai, New York, NY, USA	Melissa Nirenberg, Rachel Saunders-Pullman
Banner Health, Phoenix, AZ, USA	Sidra Aslam
The Queen's Medical Center, Honolulu, HI, USA	Michiko Kimura Bruno
LSU Health Shreveport, Shreveport, LA, USA	Elizabeth Disbrow
University of California, Berkeley, Berkeley, CA, USA	Randy Schekman
NYU Grossman School of Medicine, New York City, NY, USA	Un Kang
VA Puget Sound Health Care System, Seattle, WA, USA	Cyrus Zabetian
University of California, Los Angeles, Los Angeles, CA, USA	Beate Ritz
Mayo Clinic, Rochester, MN, USA	Bradley Boeve, Zbigniew K. Wszolek
Hue University, Huế, Vietnam	Duan Nguyen, Toan Nguyen
University of Zambia, Lusaka, Zambia	Masharip Atadzhanov